Summary

Eligibility
for people ages 13-39 (full criteria)
Location
at UCSD
Dates
study started
completion around
Principal Investigator
by Hari Narayan, MD (ucsd)

Description

Summary

Anthracycline chemotherapies (e.g. doxorubicin, daunorubicin) are commonly given to treat pediatric cancer, and carry a risk of cardiotoxicity. Over the long term, children who receive these therapies have an increased risk of heart failure and early cardiovascular death. However, current strategies for identifying patients who are at risk prior to the development of significant changes in heart function are limited. This study will focus on imaging markers of cardiac injury and dysfunction with the goal of developing improved diagnostic tests and treatment strategies.

Official Title

Cancer Therapy Effects on the Heart: Identification of Early Markers of Cardiac Disease Progression After Cardiotoxic Childhood Cancer Therapy Using Cardiac Magnetic Resonance Imaging

Details

Anthracycline chemotherapies (e.g. doxorubicin, daunorubicin) are commonly given to treat pediatric cancer, and carry a risk of cardiotoxicity. Over the long term, children who receive these therapies have an increased risk of heart failure and early cardiovascular death. However, current strategies for identifying patients who are at risk prior to the development of significant changes in heart function are limited. This study will focus on imaging markers of cardiac injury and dysfunction with the goal of developing improved diagnostic tests and treatment strategies.

Cardiac remodeling, function, and tissue characteristics will be examined using cardiac MRI data in combination with standard cardiac assessments (by echocardiography, electrocardiograms, and cardiac MRI) to assess the cardiotoxic effects of cancer therapy. Analyses will be performed in a cohort of adolescents and young adults with a history of childhood cancer.

Keywords

Cardiotoxicity, Pediatric Cancer, Heart Failure, Cardiac magnetic resonance imaging (MRI), Echocardiography, Electrocardiogram

Eligibility

You can join if…

Open to people ages 13-39

  • English and Spanish speaking male and female subjects, ages 13-39 years old
  • Diagnosis of cancer at age <22 years
  • Previously treated with anthracyline therapy for cancer, with diagnosis at least two years prior.

You CAN'T join if...

  • Patients who have a contraindication to cardiac MRI, including the presence of non-MRI compatible metallic implants.
  • Medical, psychiatric, and/or social disorder that would prevent successful completion of planned study testing or would preclude the subject from undergoing the cardiac MRI without anesthesia.
  • Patients with a history of congenital heart disease (more significant than a history of patent foramen ovale or patent ductus arteriosus).
  • Patients with orthodontic braces or metallic implants in the thorax or abdomen/lumbar spine, even if MRI-compatible, will be excluded as these may cause artifacts and limit image quality.
  • Pregnancy.

Location

  • Rady Children's Hospital accepting new patients
    San Diego California 92123 United States

Lead Scientist at University of California Health

  • Hari Narayan, MD (ucsd)
    Dr. Hari Narayan is a board-certified pediatric cardiologist at Rady Children's Hospital-San Diego and an assistant professor at UC San Diego School of Medicine. He specializes in cardiac imaging (echocardiography and cardiac magnetic resonance imaging). As a clinician and researcher, he seeks to improve the care of cancer patients receiving cardiotoxic therapies.

Details

Status
accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
Hari Narayan
ID
NCT04262830
Study Type
Observational
Participants
Expecting 60 study participants
Last Updated